Riva Therapeutics

Riva Therapeutics is an early-stage, private biotech company pioneering 'precision-lethal' small molecule therapies for oncology. Its approach targets essential tumor cell processes identified through genomic dependencies, aiming for high efficacy and tolerability in broad patient populations, potentially addressing up to a third of all cancer patients. The company is in a pre-clinical or early discovery stage, operating with a focus on speed and innovation from its base in San Diego, California.

A platform leveraging deep knowledge of genomic dependencies to discover small molecule 'precision-lethal' therapies that target essential tumor cell processes beyond DNA damage repair, using a synthetic lethal approach.

Riva competes in the crowded targeted oncology space against both large pharma and numerous biotechs. Its differentiation hinges on its focus on non-DDR synthetic lethality with small molecules, competing with companies targeting transcription, splicing, and other core cellular processes.